Supplemental vitamin D may not significantly lower the risk of fractures in generally healthy adults compared with placebo, according to a large study by LeBoff et al.
Search results for: calcium
FDA Approves Abaloparatide to Treat Men with Osteoporosis & a High Risk of Fracture
In late December, the FDA approved subcutaneous abaloparatide for the treatment of men with osteoporosis at a high risk of fracture. This approval is based on a placebo-controlled study that showed abaloparatide led to significant increases in bone mineral density of the lumbar spine, total hip and femoral neck. Abaloparatide was approved in April 2017 for the treatment of postmenopausal women with osteoporosis at high risk for fracture.
Case Report: Adult-Onset Still’s Disease with Complications
The following report outlines a case of newly diagnosed adult-onset Still’s disease (AOSD) complicated by macrophage activation syndrome (MAS) in a previously healthy and active 32-year-old man who had emigrated from Africa to the U.S. Case A man with no prior medical history presented with acute-onset polyarthritis, fevers and fatigue that began one month previously….
Patients on Dialysis Taking Denosumab May Be at Risk of Severe Hypocalcemia
The FDA is investigating the risk of severe hypocalcemia with serious outcomes, such as hospitalization and death, in patients on dialysis taking denosumab.
Pseudo-What? Exploring the Classification Criteria Development Process for CPPD
PHILADELPHIA—The term pseudogout has been a source of confusion among rheumatologists, especially as our understanding of calcium pyrophosphate crystal deposition (CPPD) disease has become more nuanced. This condition has many complex and interesting facets that warrant closer investigation. An ACR Convergence 2022 session sought to update the audience on the progress to date in developing…
Gout Research at a Glance
PHILADELPHIA—Approximately 60 research abstracts on gout were accepted for presentation at ACR Convergence 2022, including two plenary abstract presentations. It is exciting to see a wealth of research on gout being undertaken worldwide. Here, we highlight important points from seven of these studies. 1. Abstract 1810: Frequency and Patterns of Opioid Use in the Management…
Lessons from Master Clinicians: An Interview with Dr. Gary Hoffman
Rheumatologists who are outstanding clinicians, provide consistently exceptional care to patients and serve as role models for colleagues and trainees are in the spotlight in our Lessons from a Master Clinician series. Here, we offer insights from clinicians who have achieved a level of distinction in the field of rheumatology. Gary Hoffman, MD, MS, MACR,…
Case Report: CPPD Presenting as Pseudosepsis
Calcium pyrophosphate crystal deposition disease (CPPD) is an arthritis caused by the accumulation of calcium pyrophosphate crystals. Despite a prevalence of 4–7% among the adult population in Europe and the U.S., it has remained a relatively under-recognized disease owing to its many clinical presentations.1 CPPD may cause an acute mono/oligoarthritis, which may mimic gout or…
Dermatologist, Rheumatologist Discuss Refractory Cutaneous Lupus Case
As a dermatologist/internist with a career-long subspecialty interest in the cutaneous manifestations of the rheumatic diseases, I found the case of refractory acute cutaneous lupus by Samantha C. Shapiro, MD, in the June 2022 issue of The Rheumatologist intriguing in several ways, and I felt my perspectives on this case might provide additional educational value…
3 New Study Summaries from AC&R: Obesity in RA, CPDD Risk Factors & SLE Disparities
1) Obesity & Treatment Response in RA Obesity & response to advanced therapies in rheumatoid arthritis Why was this study done? There have been questions regarding whether certain therapies for rheumatoid arthritis (RA) are less effective in patients with obesity, particularly for tumor necrosis factor (TNF) inhibitors, because adipose tissue is known to generate TNF,…
- « Previous Page
- 1
- 2
- 3
- 4
- …
- 22
- Next Page »